The company said screening and diagnosis were still below pre-pandemic levels, but Biktarvy and Descovy brought HIV sales back into positive territory.
Gilead Sciences, Inc. saw its HIV business return to growth as its oncology business also saw a significant increase in revenue during the first quarter, led by the antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) and the company's cell therapy franchise.
Gilead announced its first quarter 2022 earnings on 28 April, which included a 3% increase in revenue overall, and a 2% increase when excluding sales of
Lupin CEO Vinita Gupta speaks on Trump’s Most Favored Nation Policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company, as she and MD Nilesh Gupta outline a five-year plan focused on complex generics and technology platforms
Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.
Shares are hit as German conglomerate lowers revenue forecast.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.
Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.
